However, randomized withdrawal trials, including Semaglutide Treatment Effect in People with Obesity (STEP) 4 and SURMOUNT 4, show that discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain (typically observed within one year of withdrawal) and a decline in cardiometabolic benefits. This evidence concerns the gene GLP1R and obesity disorder.